Key result
Implantable pulmonary artery pressure monitoring cuts heart failure hospitalizations ~35% versus usual care.
Why the study?
Although various remote monitoring strategies for chronic heart failure have been widely studied, their comparative effectiveness had not been systematically assessed in a network meta-analysis.
Do remote monitoring interventions (such as implantable pulmonary artery pressure sensors, AI-assisted integrated remote management, wearable sensors, telemonitoring, or structured telephone support) reduce all-cause mortality and heart failure-related hospitalizations compared to usual care or each other in adults with chronic heart failure?
Meta-Analysis (n=68,420)
Open-label and blinded outcome assessment across included trials
Randomized controlled trials (parallel group, crossover with washout ≥ 3 months, cluster-RCT)
Yes
Do remote monitoring interventions (such as implantable pulmonary artery pressure sensors, AI-assisted integrated remote management, wearable sensors, telemonitoring, or structured telephone support) reduce all-cause mortality and heart failure-related hospitalizations compared to usual care or each other in adults with chronic heart failure?
In this comprehensive network meta-analysis of 112 RCTs (68,420 patients), implantable pulmonary artery pressure sensors (IPAP) provided the most robust reductions in all-cause mortality and heart failure hospitalizations for chronic HFrEF, while AI-assisted remote management emerged as the second most effective strategy.
Answers are grounded in this paper and cite their sources.
Implantable pulmonary artery pressure sensors merit priority in heart failure remote monitoring; confirms superiority over alternatives for reducing mortality and hospitalizations.
Background: Chronic Heart Failure (CHF) affects over 64 million people globally, with high hospitalization rates and 5-year mortality comparable to many cancers. Remote monitoring Strategies-Structured Telephone Support (STS), Non-Invasive Telemonitoring (NIT), Wearable Sensors (WMS), implantable pulmonary artery pressure sensors (IPAP), AI-Assisted Integrated Remote Management (AI-IRM), and Combined Multimodal Programs (CMP)-have been widely studied, but their comparative effectiveness has not been systematically assessed in a Network Meta-Analysis (NMA). Methods and Findings: We systematically searched multiple databases through 15 December 2025. Primary outcomes were all-cause mortality and HF hospitalization; secondary outcomes included cardiovascular mortality, quality of life, exercise capacity, NT-proBNP, NYHA class, and cost-effectiveness. Two reviewers screened studies, extracted data, and assessed risk of bias using RoB 2; certainty was rated with GRADE. We identified 112 RCTs enrolling 68,420 patients across 34 countries. IPAP ranked highest for mortality (SUCRA 87%; RR 0.80, 95% CI 0.70–0.91, moderate certainty) and HF hospitalization (SUCRA 91%; RR 0.65, 95% CI 0.56–0.75, high certainty). AI-IRM ranked second for both outcomes (mortality SUCRA 74%; RR 0.83, 95% CI 0.73–0.94, low certainty; HF hospitalization SUCRA 79%; RR 0.72, 95% CI 0.63–0.82, moderate certainty). STS and NIT provided modest, low-certainty reductions (RR 0.88–0.90). Trial sequential analysis confirmed conclusive evidence for IPAP. Network consistency was acceptable (Q_inc P = 0.21). Conclusions: IPAP offers the most robust and clinically meaningful benefit for HFrEF patients. AI-IRM is a promising emerging approach requiring confirmatory trials. STS and NIT remain appropriate for patient’s ineligible for advanced monitoring. Evidence gaps in HFpEF and in low- and middleincome settings define key priorities for future research.
No takes yet. Share an insight, caveat, or question.
Andrès et al. (2026) conducted a meta-analysis in Chronic Heart Failure (n=68,420). Implantable pulmonary artery pressure sensors (IPAP) and other remote monitoring strategies (AI-IRM, CMP, WMS, NIT, STS) vs. Usual Care (UC) was evaluated on Heart failure-related hospitalization (co-primary with all-cause mortality; IPAP vs. Usual Care) (RR 0.65, 95% CI 0.56–0.75, p=<0.001). Implantable pulmonary artery pressure sensors ranked highest among remote monitoring strategies, reducing HF hospitalizations by 35% and all-cause mortality by 20% vs usual care.
Synapse has enriched 10 related papers. Consider them for comparative context: